Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants

Summary

This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a multiple-dose escalation study (Part2,MAD study phase). It's aimed to evaluate the safety, tolerability, and pharmacokinetics (PK) of ACT500 in healthy adult participants, and to explore possible metabolites and biomarkers of ACT500.

Timeline

Start

2025-03-06

Primary completion

2025-09-22

Completion

2025-09-22

Drugs

Indications